Nitisinone Dipharma (Nitisinone)

Nitisinone blocks the enzyme 4‑hydroxyphenylpyruvate dioxygenase (HPPD) in the tyrosine degradation pathway. This inhibition prevents the formation of toxic downstream metabolites that cause organ damage in hereditary tyrosinemia type I.

The prescribed dose of Nitisinone Dipharma is determined by the treating physician based on the patient’s age, weight, disease severity, and laboratory results. Dosage adjustments are made according to clinical response and safety monitoring.

Safety data for nitisinone in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nitisinone is the primary disease‑modifying therapy for hereditary tyrosinemia type I, directly targeting the metabolic defect. Alternative options such as liver transplantation address organ failure but do not correct the underlying metabolic pathway. Nitisinone therefore offers a less invasive, targeted approach.

Nitisinone Dipharma tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children.

The medication is supplied as oral tablets and is taken by mouth with water. It is usually administered once daily, but the exact schedule is set by the prescribing clinician based on individual patient needs.

Serious risks include hepatotoxicity, severe hypoglycemia, peripheral neuropathy, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver function and any signs of severe adverse reactions.

Patients with known hypersensitivity to nitisinone or any of its excipients should avoid the product. Caution is advised in individuals with severe liver disease, uncontrolled diabetes, or those taking interacting medications listed under major interactions.